Curcumin

Mechanism of action

Proposed mechanisms (mainly from preclinical studies and partly supported by clinical biomarkers): - Modulation of inflammation: inhibition of NF-κB and reduction in the expression of pro-inflammatory mediators (e.g. TNF-α, IL-6, COX-2, iNOS) in various models. - Activation of antioxidant responses: activation of the Nrf2/ARE pathway with increased defense enzymes (e.g. HO-1, SOD, catalase) and reduction of lipid peroxidation markers in some studies. - Effects on signaling and metabolism: interactions with AMPK, PPAR-γ, and pathways related to insulin sensitivity and lipid metabolism (variable clinical evidence). - Modulation of endothelial function: potential improvement in NO bioavailability and reduction of vascular oxidative stress. - Interaction with proteins and membranes: pleiotropic activity also linked to physicochemical properties (lipophilicity) and to metabolites/conjugates; the physiological relevance of metabolites in humans is still under study. Note: many mechanistic effects are dose-dependent and observed at concentrations that are difficult to achieve with unformulated curcumin.

Supported benefits

• Reduction in pain and improvement in function in osteoarthritis (especially knee) versus placebo; in some studies, efficacy comparable to NSAIDs on certain endpoints, with a different tolerability profile (moderate)
• Improvement in some inflammatory/oxidative markers (e.g. CRP in some contexts; oxidative stress markers), with heterogeneous results across studies and formulations (limited)
• Improvement in cardiometabolic parameters in some subjects (e.g. fasting glucose, HbA1c, triglycerides, LDL), with high variability and possible dependence on baseline status and formulation (limited)
• Support for depressive/anxious symptoms in some trials (often as an adjunct), with methodological heterogeneity and possible bias (emerging)
• Effects on endothelial function and blood pressure in some studies, but not consistent across all endpoints and populations (emerging)
• Longevity endpoints (cellular senescence, telomeres, hard aging outcomes): insufficient direct clinical evidence; biological plausibility is mainly preclinical (emerging)

Safety & side effects

• Gastrointestinal disturbances (nausea, dyspepsia, diarrhea, cramps), more likely at high doses or in sensitive individuals
• Headache or dizziness (less common)
• Rare skin/allergic reactions
• Possible increase in bleeding risk in predisposed individuals or in combination with antiplatelet/anticoagulant drugs (clinical evidence is not unequivocal, but pharmacological plausibility exists)

FAQ

Are curcumin and turmeric the same thing?

No. Turmeric is the spice (rhizome) that contains a mixture of compounds; curcumin is one of the main curcuminoids. Supplements often contain concentrated and standardized extracts, with absorption profiles and doses that are very different from culinary use.

Why is there so much talk about bioavailability?

Unformulated curcumin has limited intestinal absorption and is rapidly metabolized. Many clinical studies use formulations that increase systemic exposure; for this reason, results are not always transferable across different products.

Is it really an “anti-aging” supplement?

The idea comes from its modulation of inflammation and oxidative stress, processes linked to aging. However, direct clinical evidence on aging endpoints (e.g. reduction in events, improvement in validated aging biomarkers) is still limited; the strongest evidence concerns some symptomatic outcomes (e.g. osteoarthritis) and intermediate biomarkers.

Is piperine always a good idea?

Piperine can increase bioavailability, but it can also increase the risk of drug interactions (inhibition of enzymes/transporters). In the case of chronic therapies, the combination requires particular caution.

What are the signs of poor tolerability?

Gastrointestinal disturbances (nausea, diarrhea, burning), worsening of biliary symptoms, and, rarely, signs compatible with liver injury. In such cases, clinical evaluation is indicated.